12/18/2006 | SS | Biomet, Icos merger deals spur action in Telik; Harrah's bets cagey; Caremark rival bid pushes Medco up
|
10/17/2006 | BT | ICOS moved to no rating by Merrill
|
10/17/2006 | BT | Market Commentary: Icos gains 16% on Lilly buyout; Millennium forfeits AnorMED; InterMune rises 25%; OSI better
|
10/17/2006 | CV | Market Commentary: Level 3 jumps, Broadwing trips on buyout; ICOS gains on Eli Lilly offer; Home Properties launches deal
|
8/4/2006 | BT | Merrill keeps ICOS at neutral
|
6/9/2006 | BT | Merrill keeps ICOS at neutral
|
6/7/2006 | BT | ICOS requests E.U. approval for once-a-day Cialis
|
5/22/2006 | BT | Dyax, ICOS to discover therapeutic antibodies
|
5/22/2006 | BT | Market Commentary: Adventrx gains after pulling deal; Dyax gains, Icos slips on pact; Cell Therapeutics declines 7%
|
5/5/2006 | BT | Merrill keeps ICOS at neutral
|
4/20/2006 | BT | Merrill keeps ICOS at neutral
|
2/8/2006 | BT | ICOS maintained at neutral by Merrill
|
2/8/2006 | BT | Market Commentary: Pfizer news sparks buyout buzz; Immtech falls; Alkermes up; Icos off; Alexion higher; Oscient down
|
1/20/2006 | BT | Merrill maintains neutral rating for ICOS
|
11/21/2005 | BT | Merrill Lynch maintains neutral rating on ICOS
|
11/14/2005 | BT | Merrill Lynch maintains ISOC at neutral
|
11/4/2005 | BT | Merrill Lynch maintains ICOS at neutral
|
10/21/2005 | BT | Merrill Lynch maintains ICOS at neutral
|
10/13/2005 | BT | Lilly ICOS joint venture kept at neutral by Merrill
|
8/5/2005 | BT | Icos estimates for Cialis cut by Merrill
|
8/4/2005 | BT | Market Commentary: ZymoGenetics follow-on upsized but discounted; Eli Lilly sells $1.5 billion variable floaters
|
7/22/2005 | BT | Icos maintained by Merrill Lynch at neutral
|
7/11/2005 | BT | Merrill biotech analysts see interest in sector ahead of second quarter earnings
|
11/24/2003 | CV | S&P: ICOS ratings unaffected by Cialis OK
|
7/16/2003 | CV | ICOS says greenshoe exercised, raising convertibles to $278.65 million
|
6/17/2003 | CV | New Issue: ICOS $250 million convertibles yield 2.0%, up 43.4%
|
6/17/2003 | CV | Market Commentary: New deal parade marches on; Lattice reoffered at 98, still dives; secondary thin, lower
|
6/16/2003 | CV | ICOS $250 million convertibles yield 2%, up 43.4%
|
6/16/2003 | CV | Market Commentary: ICOS, Lattice at bat; buzz puts Nextel Partners eyeing another convert after new junk offering
|